Olema Pharmaceuticals is a biotechnology company specializing in therapies for women's cancers, with a particular emphasis on breast cancer. The company's strategy centers on advancing its proprietary drug candidate, OP-1250, through clinical development to address significant unmet medical needs.How does the sale value compare to recent stock performance? The weighted average sale price of around $29.73 per share was 7.5% above the Dec. 19 market close of $27.93, amid a one-year total return of 326.50% as ...

In a parallel action, the U.S. Attorney’s Office for the District of New Jersey also filed a variety of criminal charges (including securities fraud, insider trading, and a variety of conspiracy charges) against the six men.None of the allegations have been proven in court.In its complaint, the regulator alleged that between June 2020 and February 2024, Kim — a San Francisco-based investment banker — tipped Saad Shoukat to nine potential merger and acquisition deals that he learned about at work.In turn, Sh ...

SAN FRANCISCO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Tuesday, January 13, 2025 at 11:15 a.m. PT (2:1 ...

Core Viewpoint - The article highlights the offerings of the Biotech Analysis Central service, which provides in-depth analysis of pharmaceutical companies and investment opportunities in the biotech sector [1][2]. Group 1: Service Offerings - Biotech Analysis Central provides a library of over 600 biotech investing articles, a model portfolio of more than 10 small and mid-cap stocks, and live chat features for investors [2]. - The service is available for $49 per month, with a discounted annual plan at $399, representing a 33.50% savings for subscribers [1]. Group 2: Analyst Background - The author, Terry Chrisomalis, is a private investor with a background in Applied Science, focusing on generating long-term value in the healthcare sector [2]. - The analysis provided aims to assist healthcare investors in making informed decisions based on comprehensive research and insights [2].

Group 1 - The Value Lab focuses on long-only value investment ideas, aiming for a portfolio yield of about 4% and has performed well over the last 5 years by engaging in international markets [1][2] - Saipem SpA is experiencing EBITDA performance that is slightly ahead of expectations, indicating positive financial momentum [2] - The Valkyrie Trading Society consists of analysts who share high conviction investment ideas that are downside limited and expected to yield non-correlated and outsized returns in the current economic environment [2] Group 2 - The Value Lab provides members with real-time portfolio updates, 24/7 chat support, regular global market news reports, feedback on stock ideas, monthly new trades, quarterly earnings write-ups, and daily macro opinions [2]

Core Insights - Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) reached a four-year high, driven by a price target increase from Jefferies [1][2] - The stock price increased by 15.43% to close at $30.68 after hitting an intra-day high of $30.97 [1] - Jefferies raised its price target for Olema from $30 to $43, indicating a 40% upside potential [2] Company Developments - Olema is conducting a clinical trial for its breast cancer therapy, palazestrant [3] - The performance of next-generation oral Selective Estrogen Receptor Degraders (SERDs) is validating the drug class, which is expected to positively impact upcoming first-line treatment trials [3] - The breast cancer treatment market presents an estimated revenue opportunity of $10 billion [3]

Core Insights - U.S. stocks exhibited mixed performance, with the Nasdaq Composite declining by over 100 points on Wednesday [1] - Daktronics, Inc. reported quarterly earnings of 35 cents per share, surpassing the analyst consensus estimate of 27 cents per share, and quarterly sales of $229.253 million, exceeding the consensus estimate of $214.077 million [1] Company Performance - Daktronics shares surged by 15.7% to $20.80 following the positive earnings report [2] - Photronics, Inc. saw its shares increase by 44% to $37.00 after reporting better-than-expected fourth-quarter results and issuing optimistic first-quarter guidance [3] - Nextdoor Holdings, Inc. gained 24.6% to $2.5050 after a positive social media mention regarding its valuation [3] - Braze, Inc. rose by 17.5% to $36.00 after raising its FY2026 adjusted EPS and sales guidance [3] - Dave & Buster's Entertainment, Inc. jumped 14% to $20.50 following its third-quarter results [3] - SuperX AI Technology Limited's shares increased by 13.8% to $19.63 [3] - GE Vernova Inc. rose by 11.8% to $699.59 after raising its FY28 outlook and dividend, along with expanding its buyback authorization [3] - DBV Technologies S.A. gained 11.2% to $19.09 [3] - Warby Parker Inc. rose by 11% to $25.77 [3] - Dyne Therapeutics, Inc. increased by 10.5% to $20.38 after announcing a $350 million public offering [3] - ABIVAX Société Anonyme rose by 8.6% to $133.24 [3] - Olema Pharmaceuticals, Inc. gained 8.1% to $28.67 [3] - The Middleby Corporation rose by 6.3% to $137.15 after an upgrade from Jefferies [3] - EchoStar Corporation increased by 5.6% to $98.80 following an upgrade from Morgan Stanley [3]

Summary of Olema Pharmaceuticals FY Conference Call Company Overview - **Company**: Olema Pharmaceuticals (NasdaqGS:OLMA) - **Focus**: Oncology, specifically breast cancer - **Lead Asset**: Palazestrant, a selective estrogen receptor degrader (SERD) in two phase 3 trials: OPERA-01 and OPERA-02 [2][30] Key Trials and Developments - **OPERA-01**: - Focuses on second- and third-line treatment for ER-positive HER2-negative breast cancer - Expected data readout in the second half of 2026 - Control arm includes Exemestane or Fulvestrant [2][32] - **OPERA-02**: - First-line trial combining palazestrant with ribociclib (Kisqali) - Currently enrolling patients [2][30] - **KAT6 Inhibitor (OP-3136)**: - Phase 1/2 program exploring monotherapy and combination therapies with fulvestrant and palazestrant [3] Industry Context - Recent advancements in the SERD space, particularly from Roche's lidERA trial, have renewed investor confidence in estrogen receptor targeting agents [4][5] - The SERD landscape has seen mixed results, with many agents failing to demonstrate efficacy in wild-type estrogen receptors [12][16] Competitive Landscape - **EMERALD Trial**: - First oral SERD (Orsurdu) showed efficacy only in ESR1 mutant patients [7][9] - **Roche Trials**: - **acelERA** and **evERA** trials showed varying results, with giredestrant demonstrating activity in mutant but not wild-type settings [11][14] - Upcoming **persevERA** trial results are anticipated to influence perceptions of OPERA-02's potential success [39] Market Potential - The potential market for palazestrant in the wild-type endocrine-resistant population is estimated at $5 billion in the U.S. [36] - The differentiation of palazestrant as a complete antagonist may provide a unique advantage over other SERDs [15][36] Formulation and Administration - Both OPERA-01 and OPERA-02 trials utilize a tablet formulation of palazestrant, with a consistent dose of 90 mg [46] - Previous phase 1/2 data included both tablet and capsule formulations, with overlapping bioavailability [48] Future Outlook - Anticipated data from the KAT6 study and ongoing trials in 2026 [50] - Continued focus on understanding the efficacy and tolerability of palazestrant in various patient populations [52]

Core Insights - Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer and other conditions [3] - The company will participate in the 8th Annual Evercore Healthcare Conference on December 3, 2025 [1] Company Overview - Olema Oncology is dedicated to transforming the standard of care for patients with breast cancer, advancing a pipeline of novel therapies [3] - The lead product candidate, palazestrant (OP-1250), is an orally available complete estrogen receptor antagonist and selective estrogen receptor degrader, currently in two Phase 3 clinical trials [3] - Olema is also developing OP-3136, a potent lysine acetyltransferase 6 inhibitor, which is in a Phase 1 clinical study [3] - The company is headquartered in San Francisco with operations in Cambridge, Massachusetts [3]

Core Insights - Olema Pharmaceuticals, Inc. has successfully closed an underwritten public offering of 11,500,000 shares of common stock at a price of $19.00 per share, generating gross proceeds of approximately $218.5 million before expenses [1]. Company Overview - Olema Oncology is a clinical-stage biopharmaceutical company focused on developing targeted therapies for breast cancer and other endocrine-driven cancers. The company is advancing a pipeline that includes its lead product candidate, palazestrant (OP-1250), which is currently in two Phase 3 clinical trials, and OP-3136, a KAT6 inhibitor in Phase 1 clinical study [5].